Cargando…
AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
We have compared five different assays for antibodies to aquaporin-4 in 181 cases of suspected Neuromyelitis optica spectrum disorders (NMOSD) and 253 controls to assess their relative utility. As part of a clinically-based survey of NMOSD in Australia and New Zealand, cases of suspected NMOSD were...
Autores principales: | Prain, Kerri, Woodhall, Mark, Vincent, Angela, Ramanathan, Sudarshini, Barnett, Michael H., Bundell, Christine S., Parratt, John D. E., Silvestrini, Roger A., Bukhari, Wajih, Brilot, Fabienne, Waters, Patrick, Broadley, Simon A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787171/ https://www.ncbi.nlm.nih.gov/pubmed/31636597 http://dx.doi.org/10.3389/fneur.2019.01028 |
Ejemplares similares
-
Molecular Pathogenesis of Neuromyelitis Optica
por: Bukhari, Wajih, et al.
Publicado: (2012) -
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation
por: Khalilidehkordi, Elham, et al.
Publicado: (2020) -
MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
por: Clarke, Laura, et al.
Publicado: (2021) -
Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018) -
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)